Ultrasonographic Tissue Thickness After Complex Decongestive Therapy in Lower-Limb Lymphedema

November 1, 2026 updated by: Abdullah Goktug Yazar, Kayseri City Hospital

Effect of Complex Decongestive Therapy on Subcutaneous Tissue Thickness in Lower-Limb Lymphedema: A Prospective Ultrasonographic Study With Contralateral Internal Control

This prospective single-center study evaluated whether 4 weeks of phase-1 complex decongestive therapy (manual lymphatic drainage, multilayer short-stretch bandaging, decongestive exercise, and skin care) changes dermal and subcutaneous tissue thickness measured by high-frequency ultrasonography in adults with unilateral International Society of Lymphology stage 1-2 lower-limb lymphedema. Measurements were made at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control and body weight was recorded to distinguish local tissue change from systemic weight change.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Participants received a standardized 20-session (5 days/week, 4 weeks) intensive-phase complex decongestive therapy program delivered by an experienced physiotherapist. Ultrasonographic measurements were performed with a 10-14 MHz linear probe using a minimal-compression technique after 15 minutes of supine rest, at the same time of day, by an assessor blinded to baseline values; intra-rater reliability (intraclass correlation coefficient 0.92) was established in 10 patients. The sample size (n = 34; Cohen's d = 0.5, power 80%, alpha 0.05; 40 recruited) was calculated with G*Power. Paired comparisons (paired t-test or Wilcoxon signed-rank test), 95% confidence intervals, Cohen's d, and Pearson correlation of treatment response with age, body mass index, and disease duration were planned.

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kayseri, Turkey (Türkiye), 38080
        • Kayseri City Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults presenting to the Physical Medicine and Rehabilitation outpatient clinic of Kayseri City Hospital with unilateral lower-limb lymphedema and an indication for intensive-phase complex decongestive therapy.

Description

Inclusion Criteria:

  • Age 18 years or older
  • Unilateral lower-limb lymphedema, International Society of Lymphology stage 1 or 2 (2020 consensus)
  • Diagnosis supported by lymphoscintigraphy
  • Indication for intensive-phase complex decongestive therapy
  • No previous full course of complex decongestive therapy on the affected limb
  • Written informed consent

Exclusion Criteria:

  • Active cellulitis or erysipelas at the measurement sites
  • Active, recurrent, or metastatic malignancy
  • Decompensated heart failure or history of deep vein thrombosis
  • Bilateral lymphedema
  • Cognitive impairment preventing adherence to treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Lower-limb lymphedema, complex decongestive therapy

Adults with unilateral ISL stage 1-2 lower-limb lymphedema who received 4 weeks (20 sessions) of phase-1 complex decongestive therapy as standard care. Dermal and subcutaneous tissue thickness were measured by high-frequency ultrasonography at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control.

Phase-1 (intensive) complex decongestive therapy delivered 5 days per week for 4 weeks (20 sessions) by an experienced physiotherapist: Vodder-technique manual lymphatic drainage (30-45 min), multilayer short-stretch compression bandaging from the toes to the proximal thigh, decongestive range-of-motion exercise performed with bandages in place, and daily skin care with a pH 5.5 moisturizer.

Other Names:
  • Complete Decongestive Therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in subcutaneous tissue thickness of the affected limb at the suprapatellar site
Time Frame: Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)

Subcutaneous tissue thickness (dermis-subcutis interface to deep fascia) measured in millimeters by B-mode ultrasonography with a 10-14 MHz linear probe using a minimal-compression technique.

Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in subcutaneous tissue thickness of the affected limb at the infrapatellar site
Time Frame: Baseline and end of week 4

Subcutaneous tissue thickness in millimeters measured by B-mode ultrasonography (10-14 MHz linear probe, minimal-compression technique).

Baseline and end of week 4
Change in dermal thickness of the affected limb at the suprapatellar and infrapatellar sites
Time Frame: Baseline and end of week 4

Dermal thickness (skin surface to dermis-subcutis interface) in millimeters measured by B-mode ultrasonography.

Baseline and end of week 4
Change in subcutaneous tissue thickness of the unaffected (control) limb
Time Frame: Baseline and end of week 4

Subcutaneous tissue thickness of the contralateral unaffected limb at the suprapatellar and infrapatellar sites, in millimeters, measured by B-mode ultrasonography; serves as an internal control.

Baseline and end of week 4
Change in body weight
Time Frame: Baseline and end of week 4

Body weight in kilograms measured on the same calibrated scale, recorded to distinguish local tissue change from systemic weight change.

Baseline and end of week 4

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of subcutaneous thickness change with disease duration, age, and body mass index
Time Frame: Baseline and end of week 4

Pearson correlation coefficients between the change in suprapatellar subcutaneous thickness of the affected limb and disease duration (months), age (years), and body mass index (kg/m2).

Baseline and end of week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Abdullah Goktug Yazar, MD, Kayseri City Hospital
  • Study Chair: Ayse Guc, MD, Kayseri City Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2025

Primary Completion (Actual)

January 1, 2026

Study Completion (Actual)

January 1, 2026

Study Registration Dates

First Submitted

November 1, 2026

First Submitted That Met QC Criteria

November 1, 2026

First Posted (Actual)

November 5, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

November 1, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe